Vanguard Group
TARS icon

Vanguard Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Vanguard Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$196M Buy
2,399,560
+127,470
+6% +$9.52M ﹤0.01% 1555
2025
Q3 		$135M Sell
2,272,090
-25,264
-1% -$1.24M ﹤0.01% 1724
2025
Q2 		$93.1M Buy
2,297,354
+70,759
+3% +$3.18M ﹤0.01% 1856
2025
Q1 		$114M Buy
2,226,595
+111,433
+5% +$5.51M ﹤0.01% 1740
2024
Q4 		$117M Buy
2,115,162
+17,839
+0.9% +$810K ﹤0.01% 1806
2024
Q3 		$69M Buy
2,097,323
+107,630
+5% +$3.03M ﹤0.01% 2048
2024
Q2 		$54.1M Buy
1,989,693
+163,061
+9% +$5.48M ﹤0.01% 2114
2024
Q1 		$66.4M Buy
1,826,632
+231,131
+14% +$6.8M ﹤0.01% 2047
2023
Q4 		$32.3M Buy
1,595,501
+43,699
+3% +$730K ﹤0.01% 2373
2023
Q3 		$27.6M Buy
1,551,802
+316,128
+26% +$5.59M ﹤0.01% 2411
2023
Q2 		$22.3M Buy
1,235,674
+10,133
+0.8% +$161K ﹤0.01% 2542
2023
Q1 		$15.4M Buy
1,225,541
+13,071
+1% +$191K ﹤0.01% 2713
2022
Q4 		$17.8M Buy
1,212,470
+276,821
+30% +$4.58M ﹤0.01% 2673
2022
Q3 		$16M Buy
935,649
+279,826
+43% +$4.44M ﹤0.01% 2728
2022
Q2 		$9.57M Buy
655,823
+197,007
+43% +$2.96M ﹤0.01% 3011
2022
Q1 		$7.72M Sell
458,816
-374
-0.1% -$6.94K ﹤0.01% 3289
2021
Q4 		$10.3M Buy
459,190
+30,200
+7% +$785K ﹤0.01% 3183
2021
Q3 		$9.24M Buy
428,990
+2,945
+0.7% +$72.9K ﹤0.01% 3287
2021
Q2 		$12.3M Buy
426,045
+153,055
+56% +$4.78M ﹤0.01% 3104
2021
Q1 		$8.8M Buy
272,990
+2,099
+0.8% +$77.6K ﹤0.01% 3222
2020
Q4 		$11.2M Buy
+270,891
New +$7.72M ﹤0.01% 2935

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Vanguard Group's TARS Position: Q4 2025 in Review

Vanguard Group increased its Tarsus Pharmaceuticals (TARS) stake by 5.6% in Q4 2025, buying an estimated $9.52M and bringing the position to 2,399,560 shares worth $196M. The position accounts for ﹤0.01% of the portfolio, ranked #1555.

Vanguard Group first reported a position in TARS in Q4 2020 and has held it in 21 quarters since. 246 funds tracked by Wall St. Rank hold TARS as of Q4 2025.

  • Vanguard Group held 2,399,560 shares of Tarsus Pharmaceuticals worth $196M as of Q4 2025.
  • Vanguard Group bought 127,470 Tarsus Pharmaceuticals shares in Q4 2025, an estimated $9.52M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1555 holding.
  • Vanguard Group first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • 246 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.